[Edaily Reporter Kim Hyung-il ] KIWOOM Securities forecasts that ISUPETASYS(007660)will continue its earnings growth momentum thanks to the expansion of high-value-added multilayer products and price hikes. Although the target price was lowered due to an adjustment in the applicable multiple following a decline in the stock prices of global peers, the firm maintained its “Buy” rating, citing the company’s competitiveness in the global application-specific integrated circuit (ASIC) market and the expansion of order volumes from new clients.
(Source: KIWOOM Securities)
On the 20th, Kwon Min-kyu, an analyst at KIWOOM Securities, reported that ISUPETASYS’s third-quarter revenue reached 389.2 billion won, a 31% increase year-over-year, while operating profit rose 62% to 94.9 billion won. The operating profit margin stood at 24.4%. While revenue and operating profit fell short of the market consensus of 431.5 billion won and 95.8 billion won, respectively, the operating profit margin exceeded the consensus estimate of 22.2%.
While revenue was weaker than expected due to exchange rate fluctuations, profitability improved. This improvement was driven by the partial reflection of the price increases implemented in the second quarter, as well as the delayed impact of lower raw material prices from the first half of the year. Excess demand, where monthly order intake exceeded production capacity, also persisted.
The order backlog at the end of the third quarter stood at 784.9 billion won, a 26% increase from the previous quarter. Based on standalone headquarters figures, high-value-added multi-layer products—which have an average selling price (ASP) more than 2.5 times that of the existing Vippo process—accounted for approximately 15% of revenue. The share of multi-layer products within the order backlog expanded to 33%.
The company projected that the effects of an improved high-value-added product mix and price increases would begin to take full effect starting in the fourth quarter. As mass production of multi-layer products—such as the TPUv8 and 800G switches—expands, the revenue share of multi-layer products is expected to rise from 15% in the third quarter to 30% in the fourth quarter, and to reach 60% by 2027. Price increases for most customers are also expected to begin taking effect in October, with the full impact expected to be felt in the fourth quarter. The company also expects the Hunan, China, subsidiary to resume its profit margin recovery as delayed price increases for key customers are implemented.
However, rising raw material prices and low yield rates for multilayer products are factors limiting the extent of profitability improvement. Price increases for key raw materials, such as copper-clad laminate (CCL), will be reflected starting in the fourth quarter, and the raw material procurement environment remains tight. The firm projected that raw material procurement conditions will gradually ease starting in the second half of next year through the securing of new, diversified suppliers.
KIWOOM Securities assessed that, despite these headwinds, there has been no change in ISUPETASYS’s fundamentals. With excess demand persisting, the firm expects strong earnings performance as factory expansions continue and the trend of increased high-value-added volumes for new customers persists. It also cited the expansion of global ASIC market share and increased volumes for new customers and hyperscalers next year as growth drivers.
The target price was set at 130,000 won, lower than the previous estimate. This reflects a downward adjustment to the applied multiples following a decline in the stock prices of global peers. However, the “Buy” investment rating was maintained, considering the company’s unrivaled position in the domestic ASIC substrate market and its upward earnings trend.
Analyst Kwon stated, “We expect the company’s strong market share in the global ASIC market to continue, along with increased shipments to new customers and hyperscalers,” adding, “As the company emerges as the optimal choice for building supply chains outside of China amid the U.S.-China trade dispute and geopolitical risks in Taiwan, its benefits are expected to gradually expand.”
BlackRock, the world’s largest asset manager, forecasts additional growth opportunities in the Bitcoin and cryptocurrency investment product markets. However, the firm predicts that tokenization will …
Mezzion Pharma Co., Ltd.(140410)has overturned a rejection decision that had been blocking the registration of a U.S. patent for the use of Udenafil in the treatment of liver disease. The company plan…
(Graphic: ChatGPT)
Celltrion(068270)’s European subsidiaries have secured supply contracts one after another in procurement tenders conducted by local hospitals and pharmaceutical purchasing organ…